To examine the effect of seven-day triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole for Helicobacter pylori (H pylori) eradication and evaluate which dose of clarithromycin is more effective for eradicating H pylori infection.
Dosing frequency of proton pump inhibitor (PPI) with clarithromycin 250 mg (13 treatment arms with 585 patients for PPI twice daily and 27 treatment arms with 1472 patients for PPI once daily): Pooled eradication rates were significantly higher with PPI twice daily compared to PPI once daily (88.7% versus 81.7%; P <= 0.001).
Study design.
There was no significant difference in eradication rates between RCTs and cohort or open trials with respect to clarithromycin dose and frequency of dosing for PMC or PAC combination therapy.
Adverse events.
Treatment related drop-outs (58 studies with 69 treatment arms and 4266 patients) and adverse events (49 studies with 55 treatment arms and 3469 patients):
PAC combination (proton pump inhibitor, clarithromycin and metronidazole): 33.7% reported adverse events and 1.2% dropped out. Significantly more patients on clarithromycin 500 mg compared clarithromycin 250 mg experienced adverse events (39.7% versus 30%; P < 0.0001) though no significant difference in drop-outs (1.7% versus 1%; P = 0.3356).
PAC combination (proton pump inhibitor, clarithromycin and amoxycillin): significantly lower rates of adverse reactions than in PMC group (21.4% versus 33.7%; P < 0.0001). Drop-out rates were similar to those of the PMC group (1.8% versus 1.2%; P = 0.1264). No significant differences were found in either adverse event rates according to clarithromycin dose.
